Mitchell S. Kapoor
Stock Analyst at HC Wainwright & Co.
(4.10)
# 491
Out of 5,148 analysts
80
Total ratings
49.28%
Success rate
15.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mitchell S. Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CBIO Crescent Biopharma | Maintains: Buy | $25 → $22 | $11.20 | +96.43% | 3 | Mar 2, 2026 | |
| SRPT Sarepta Therapeutics | Reiterates: Sell | $5 | $16.32 | -69.36% | 4 | Mar 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Neutral | $55 | $59.74 | -7.93% | 5 | Mar 2, 2026 | |
| SMMT Summit Therapeutics | Maintains: Buy | $40 → $30 | $16.19 | +85.30% | 8 | Feb 24, 2026 | |
| TYRA Tyra Biosciences | Maintains: Buy | $30 → $45 | $32.52 | +38.38% | 2 | Feb 17, 2026 | |
| INCY Incyte | Reiterates: Buy | $135 | $100.04 | +34.95% | 2 | Feb 11, 2026 | |
| EVMN Evommune | Maintains: Buy | $35 → $65 | $25.61 | +153.81% | 2 | Feb 10, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $20 | $11.53 | +73.46% | 3 | Jan 29, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $15 → $25 | $15.44 | +61.92% | 6 | Jan 28, 2026 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $50 | $18.44 | +171.15% | 2 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $17.98 | +39.04% | 2 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $20.74 | +237.51% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $7.13 | +40.25% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 → $40 | $29.72 | +34.59% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.58 | - | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $69.85 | +28.85% | 5 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 → $45 | $24.10 | +86.72% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.58 | +163.85% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $30 | $7.60 | +294.74% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $10 | $5.34 | +87.27% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $110 | $81.96 | +34.21% | 6 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $20 | $8.51 | +135.02% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $40 | $33.69 | +18.73% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $60.77 | +31.64% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.15 | +132.56% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.53 | +357.52% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $6.76 | -70.41% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.16 | +244.83% | 1 | Aug 11, 2025 |
Crescent Biopharma
Mar 2, 2026
Maintains: Buy
Price Target: $25 → $22
Current: $11.20
Upside: +96.43%
Sarepta Therapeutics
Mar 2, 2026
Reiterates: Sell
Price Target: $5
Current: $16.32
Upside: -69.36%
BioMarin Pharmaceutical
Mar 2, 2026
Reiterates: Neutral
Price Target: $55
Current: $59.74
Upside: -7.93%
Summit Therapeutics
Feb 24, 2026
Maintains: Buy
Price Target: $40 → $30
Current: $16.19
Upside: +85.30%
Tyra Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $30 → $45
Current: $32.52
Upside: +38.38%
Incyte
Feb 11, 2026
Reiterates: Buy
Price Target: $135
Current: $100.04
Upside: +34.95%
Evommune
Feb 10, 2026
Maintains: Buy
Price Target: $35 → $65
Current: $25.61
Upside: +153.81%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $20
Current: $11.53
Upside: +73.46%
Intellia Therapeutics
Jan 28, 2026
Maintains: Buy
Price Target: $15 → $25
Current: $15.44
Upside: +61.92%
Legend Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $60 → $50
Current: $18.44
Upside: +171.15%
Jan 15, 2026
Reiterates: Buy
Price Target: $25
Current: $17.98
Upside: +39.04%
Jan 13, 2026
Reiterates: Buy
Price Target: $70
Current: $20.74
Upside: +237.51%
Jan 13, 2026
Maintains: Buy
Price Target: $13 → $10
Current: $7.13
Upside: +40.25%
Jan 9, 2026
Reiterates: Buy
Price Target: $20 → $40
Current: $29.72
Upside: +34.59%
Jan 7, 2026
Downgrades: Neutral
Price Target: n/a
Current: $8.58
Upside: -
Dec 19, 2025
Reiterates: Buy
Price Target: $90
Current: $69.85
Upside: +28.85%
Dec 9, 2025
Upgrades: Buy
Price Target: $20 → $45
Current: $24.10
Upside: +86.72%
Nov 24, 2025
Initiates: Buy
Price Target: $20
Current: $7.58
Upside: +163.85%
Nov 19, 2025
Maintains: Buy
Price Target: $40 → $30
Current: $7.60
Upside: +294.74%
Nov 11, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $5.34
Upside: +87.27%
Nov 10, 2025
Maintains: Buy
Price Target: $100 → $110
Current: $81.96
Upside: +34.21%
Oct 27, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $8.51
Upside: +135.02%
Oct 27, 2025
Maintains: Buy
Price Target: $45 → $40
Current: $33.69
Upside: +18.73%
Sep 23, 2025
Reiterates: Buy
Price Target: $80
Current: $60.77
Upside: +31.64%
Sep 5, 2025
Reiterates: Buy
Price Target: $5
Current: $2.15
Upside: +132.56%
Aug 19, 2025
Reiterates: Buy
Price Target: $7
Current: $1.53
Upside: +357.52%
Aug 19, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $6.76
Upside: -70.41%
Aug 11, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.16
Upside: +244.83%